Scientists at Stanford Medicine used artificial intelligence to comb through the human genome and surface a natural molecule that curbs appetite — one they say worked in animals without the nausea and other side effects common to Ozempic-style drugs.
How AI found it
The team built an algorithm called Peptide Predictor that scanned all ~20,000 human protein-coding genes for the signatures of hormone-like peptides. It narrowed hundreds of thousands of possibilities down to a shortlist, ultimately spotlighting a 12-amino-acid peptide they named BRP (derived from a prohormone called BRINP2).
“The algorithm was absolutely key to our findings,” said senior author Katrin Svensson of Stanford Medicine.
Why it might be gentler
The proposed advantage comes down to where the molecule acts. Semaglutide (Ozempic) hits receptors across the brain, gut, and pancreas — which is part of why it can cause nausea and constipation. BRP appears to act more narrowly, in the hypothalamus, the brain's appetite-and-metabolism control center. In lean mice and minipigs, it suppressed appetite and reduced food intake by up to 50%, with fat loss and without the muscle loss or nausea seen with GLP-1 drugs.
The important caveat
This is early. The results, published in Nature, come from animals — human trials are only planned. Many promising weight-loss compounds look great in mice and disappoint in people, and “no side effects in animals” is not the same as safe in humans. Still, it's a striking demonstration of AI accelerating drug discovery. This article is general information, not medical advice.